European regulators are watching Johnson & Johnson's vaccine for unusual blood clots
- European regulators are investigating whether Johnson & Johnson's vaccine could cause blood clots.
- The investigation was opened after four cases were reported, including one fatality.
- J&J's vaccine was authorised for European distribution last month, but hasn't been given out yet.
- For more articles, go to www.BusinessInsider.co.za.
European regulators are investigating whether Johnson & Johnson's Covid-19 vaccine caused unusual blood clotting after four cases were reported in vaccine recipients, including one fatality.
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee disclosed Friday that they are reviewing the vaccine after three people who received J&J's vaccine in the US and another who was involved in a clinical trial developed blood clots. It's currently not clear if the vaccine caused these clots.
J&J did not immediately respond to a request for comment.
The investigation comes as European states prepare to add the vaccine to their roster of Covid-19 shots. J&J's vaccine was recommended for authorisation by the EMA on March 11, but has not yet been distributed.
It's not the first time the link between vaccines and blood clots has been investigated
The EMA has been closely watching reports of blood clots linked to another vaccine: AstraZeneca's two-dose immunisation.
The agency stated Wednesday that blood clots can be a "very rare" side effect of AstraZeneca's shot in people with low blood platelet levels. Approximately 169 cases of blood clots in the brain and 53 cases of blood clots in the spleen had been reported as of April 4, according to the EMA.
Issues have been popping up as J&J's shot has rolled out in the US.
One of the factories that produces both drug companies' vaccines is in hot water after it was reported by the New York Times that 15 million doses of Johnson & Johnson's vaccine had been cross-contaminated with AstraZeneca's vaccine at a U.S. factory run by Emergent BioSolutions. None of those shots were distributed to the public.
Officials in Colorado and North Carolina stopped giving out J&J's vaccine this week after two dozen people experienced minor adverse reactions like nausea and dizziness.
J&J's stock traded down about 1% on Friday morning.
Receive a daily news update on your cellphone. Or get the best of our site emailed to you
Go to the Business Insider front page for more stories.